MAM
PACB icon

Mark Asset Management’s Pacific Biosciences PACB Stock Holding History

Mark Asset Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-96,319
Closed -$1.26M – 54
2015
Q4 		$1.26M Buy
+96,319
New +$864K 0.32% 40

Other funds holding PACB

MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Mark Asset Management's PACB Position: Q1 2016 in Review

Mark Asset Management sold out of Pacific Biosciences (PACB) in Q1 2016, closing a stake of 96,319 shares — an estimated $1.26M sold.

Mark Asset Management first reported a position in PACB in Q4 2015 and held it in 1 quarter. The position peaked at $1.26M in Q4 2015. 129 funds tracked by Wall St. Rank hold PACB as of Q1 2016.

  • Mark Asset Management reported no remaining Pacific Biosciences position as of Q1 2016 after selling out during the quarter.
  • Mark Asset Management sold 96,319 Pacific Biosciences shares in Q1 2016, an estimated $1.26M.
  • Mark Asset Management first reported a position in Pacific Biosciences in Q4 2015 and held it in 1 quarter.
  • Mark Asset Management's Pacific Biosciences position peaked at $1.26M in Q4 2015.
  • 129 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2016.

Based on Mark Asset Management's 13F filing for Q1 2016, filed 13 May 2016.